Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00733850Phase 2Completed

Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Role: lead

NCT01483586Phase 2Terminated

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Role: lead

NCT01640730Phase 2Terminated

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Role: lead

NCT00031031Phase 1Completed

Kanglaite Injection Phase I Study

Role: lead

All 4 trials loaded